Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study to Evaluate the Safety and Pharmacokinetics of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

NCT04143724 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04143724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04143724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study to Evaluate the Safety and Pharmacokinetics of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Recruiting
Start date
November 7, 2019
Completion date
August 31, 2035
Enrollment
99 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia